Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
The agency also granted traditional approval to acalabrutinib as a single agent for adults with previously treated MCL. Acalabrutinib